<SEC-DOCUMENT>0001140361-22-012456.txt : 20220401
<SEC-HEADER>0001140361-22-012456.hdr.sgml : 20220401
<ACCEPTANCE-DATETIME>20220401063021
ACCESSION NUMBER:		0001140361-22-012456
CONFORMED SUBMISSION TYPE:	NT 10-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220401
DATE AS OF CHANGE:		20220401
EFFECTIVENESS DATE:		20220401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Brooklyn ImmunoTherapeutics, Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		NT 10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		22795756

	BUSINESS ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALROY INDUSTRIES INC
		DATE OF NAME CHANGE:	19850411
</SEC-HEADER>
<DOCUMENT>
<TYPE>NT 10-K
<SEQUENCE>1
<FILENAME>brhc10035898_nt10k.htm
<DESCRIPTION>NT 10-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
  <div>
    <div style="text-align: center; font-weight: bold;"><a name="z_wd_lastPlace"></a><font style="font-size: 14pt;">UNITED STATES</font></div>
    <font style="font-size: 14pt;"> </font>
    <div style="text-align: center; font-weight: bold; font-size: 14pt;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-weight: bold; font-size: 12pt;">Washington, D.C. 20549</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold; font-size: 18pt;">FORM 12b-25</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z18a5744a7b1e408490eaa6da46565916">

        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td colspan="1" style="width: 40%; vertical-align: top; padding-bottom: 2px; text-align: right;">SEC File Number: </td>
          <td style="width: 10%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="font-family: 'Times New Roman', Times, serif;">001-11460</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z8f5c2603fa444a5b9af360426ba8ad36">

        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td colspan="1" style="width: 38%; vertical-align: top; padding-bottom: 2px; text-align: right;">CUSIP Number:</td>
          <td style="width: 12%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="font-family: 'Times New Roman', Times, serif;">114082100</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">NOTIFICATION OF LATE FILING</div>
    <br>
    <table cellspacing="0" cellpadding="0" border="0" class="cfttable" id="z1d2192a6126149ada159100d33822fc1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

        <tr>
          <td style="vertical-align: top; width: 9%;">
            <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">(Check One)</font>:</div>
          </td>
          <td rowspan="1" colspan="4" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">&#9746;Form 10-K&#160;&#160; <a name="Check13"></a>&#9744; Form 20-F&#160;&#160; &#9744; Form 11-K&#160; &#160;&#160; &#9744;<font style="font-family: 'Wingdings 2', serif;"></font> Form 10-Q&#160; &#160; &#9744; Form 10-D&#160;&#160; &#9744; Form N-CEN<font style="font-family: 'Wingdings 2', serif;"></font></div>
            <div style="font-family: 'Times New Roman', Times, serif;">&#9744;&#160; Form N-CSR</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 9%; padding-bottom: 2px;">&#160;</td>
          <td colspan="1" style="vertical-align: top; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td style="vertical-align: top; width: 13%; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">For Period Ended:</div>
          </td>
          <td colspan="1" style="vertical-align: top; width: 47%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif;">December 31, 2021</div>
          </td>
          <td colspan="1" style="vertical-align: top; width: 30%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 9%;">&#160;</td>
          <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>
          <td colspan="1" style="vertical-align: top; width: 13%;">&#160;</td>
          <td style="vertical-align: top; width: 47%;">&#160;&#160;&#160;</td>
          <td colspan="1" style="vertical-align: top; width: 30%;">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 9%;">&#160;</td>
          <td rowspan="1" colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">&#9744;&#160;&#160; Transition Report on Form 10-K</div>
          </td>
          <td colspan="1" style="vertical-align: top; width: 30%;">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 9%;">&#160;</td>
          <td rowspan="1" colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">&#9744;&#160;&#160; Transition Report on Form 20-F</div>
          </td>
          <td colspan="1" style="vertical-align: top; width: 30%;">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 9%;">&#160;</td>
          <td rowspan="1" colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">&#9744;&#160;&#160; Transition Report on Form 11-K</div>
          </td>
          <td colspan="1" style="vertical-align: top; width: 30%;">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 9%;">&#160;</td>
          <td rowspan="1" colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">&#9744;&#160;&#160; Transition Report on Form 10-Q</div>
          </td>
          <td colspan="1" style="vertical-align: top; width: 30%;">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 9%;">&#160;</td>
          <td rowspan="1" colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">For the Transition Period Ended:</div>
          </td>
          <td colspan="1" style="vertical-align: top; width: 30%;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.</div>
    <div><br>
    </div>
    <div>If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:<br>
      <br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="font-weight: bold;">PART I -- REGISTRANT INFORMATION</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zd37430e0d63f4ee48e987087376fb96f">

        <tr>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>Brooklyn ImmunoTherapeutics, Inc.</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div>Full Name of Registrant</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div>Former Name if Applicable</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 80%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>140 58th Street, Suite 2100</div>
          </td>
          <td style="width: 20%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div>Address of Principal Executive Office<font style="font-style: italic;"> (Street and Number)</font></div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>Brooklyn, New York 11220</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div>City, State and Zip Code</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="font-weight: bold;">PART II -- RULES 12b-25(b) AND (c)</div>
    <div><br>
    </div>
    <div>If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zd27e7fb1fd3b4b1c81a645224b139aa9">

        <tr>
          <td style="width: 3%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 3%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">(a)</div>
          </td>
          <td style="width: 94%; vertical-align: top;">
            <div>The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0);">
            <div>&#160;</div>
            <div>&#9746;</div>
          </td>
          <td style="width: 3%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">(b)</div>
          </td>
          <td style="width: 94%; vertical-align: top;">
            <div>The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed&#160; on or before the fifteenth calendar day following the prescribed due date; or
              the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 3%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">(c)</div>
          </td>
          <td style="width: 94%; vertical-align: top;">
            <div>The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="font-weight: bold;">PART III-- NARRATIVE</div>
    <div><br>
    </div>
    <div>State below in reasonable detail why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR or the transition report portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed.)</div>
    <div><br>
    </div>
    <div>Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;, &#8220;<u>we</u>&#8221;, &#8220;<u>us</u>&#8221; or &#8220;<u>our</u>&#8221;), is filing this Notification of Late Filing on Form 12b-25 with respect to its Annual Report on Form 10-K for the year ended
      December 31, 2021 (the &#8220;<u>Form 10-K</u>&#8221;).</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The Company could not file the Form 10-K within the prescribed time period required for smaller reporting companies without unreasonable effort and expense because additional time is required by the Company&#8217;s
      management, working in conjunction with the Company&#8217;s independent auditors, to complete the Company&#8217;s audit for the year ended December 31, 2021.&#160; The Company is diligently working with its auditors and anticipates that it will file the Form 10-K no
      later than the fifteenth calendar day following the prescribed due date.</div>
    <div><br>
    </div>
    <div style="font-weight: bold;">PART IV -- OTHER INFORMATION</div>
    <div><br>
    </div>
    <div>(1)&#160; Name and telephone number of person to contact in regard to this notification</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" align="center" style="border-collapse: collapse; width: 90%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;" id="z98f307b80914460db768f61e92db22fd">

        <tr>
          <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">Sandra Gurrola</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 17.58%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">(619)</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">957-3015</div>
          </td>
        </tr>
        <tr>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-align: center;">(Name)</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 17.58%; vertical-align: top;">
            <div style="text-align: center;">(Area Code)</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center;">(Telephone Number)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>(2)&#160; Have all other periodic&#160; reports&#160; required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter&#160; period that the registrant was
      required to file such report(s) been filed? If the answer is no, identify report(s).&#9746; Yes&#160; &#9744; No</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z7450e42ec8dc45a3b8a9d8ea09722640" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>(3)&#160; Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?</div>
    <div style="text-align: right; text-indent: 36pt; margin-left: 360pt; font-family: 'Times New Roman',Times,serif;">&#9746;<font style="font-family: 'Times New Roman';"> Yes&#160; &#9744; No</font></div>
    <div><br>
    </div>
    <div>If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zcaac458e3d2b446791b144920b24a6ad">

        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">(See Annex A)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z60f7be88df284b38820503a8ca4c8f86">

        <tr>
          <td style="width: 20%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 60%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-size: 24pt;">Brooklyn ImmunoTherapeutics, Inc.</div>
          </td>
          <td style="width: 20%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top;">&#160;</td>
          <td style="width: 60%; vertical-align: top;">
            <div style="text-align: center;">(Name of Registrant as Specified in Charter)</div>
          </td>
          <td style="width: 20%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <div>has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.</div>
      <div> <br>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="za4af2c52afbc4e0ba2e0bd7056fee010">

        <tr>
          <td colspan="1" style="width: 5%; vertical-align: top; padding-bottom: 2px;">Date </td>
          <td style="width: 25%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>April 1, 2022</div>
          </td>
          <td colspan="1" style="width: 20%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div>By</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Howard Federoff</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zc675d33553c64dbaac4f6544d71699d7">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 45%; vertical-align: top;">
            <div>Howard Federoff</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 45%; vertical-align: top;">
            <div>Chief Executive Officer and President</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center;">Annex A</div>
    <div><br>
    </div>
    <div style="text-align: justify;">As previously reported, on August 12, 2020, the Company (then known as &#8220;<u>NTN Buzztime, Inc.</u>&#8221;), Brooklyn LLC and BIT Merger Sub, Inc., a wholly owned subsidiary of the Company (&#8220;<u>Merger Sub</u>&#8221;), entered into
      an agreement and plan of merger and reorganization (the &#8220;<u>Merger Agreement</u>&#8221;) pursuant to which, among other matters, Merger Sub merged with and into Brooklyn LLC, with Brooklyn LLC continuing as a wholly owned subsidiary of the Company and as
      the surviving company of the merger (the &#8220;<u>Merger</u>&#8221;). The Merger closed on March 25, 2021. After the Merger, the Company changed its name from &#8220;NTN Buzztime, Inc.&#8221; to &#8220;Brooklyn ImmunoTherapeutics, Inc.&#8221; The Merger was accounted for as a reverse
      acquisition, in which Brooklyn LLC was deemed the acquiring company for accounting purposes.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">In accordance with the Merger Agreement, on March 25, 2021, the Company amended its restated certificate of incorporation in order to effect:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4f1cde5eafc74ce7b49b8ce6d733559b">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>prior to the Merger, a reverse stock split of its common stock, par value $0.005 per share, at a ratio of one-for-two; and</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z99a24d4761424d3e8f9361f4d93cc9df">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>following the Merger, a change in its corporate name from &#8220;NTN Buzztime, Inc.&#8221; to &#8220;Brooklyn ImmunoTherapeutics, Inc.&#8221;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;">On March 26, 2021, we sold the rights, title and interest in and to the assets relating to the business operated under the name &#8220;NTN Buzztime, Inc.&#8221; prior to the Merger to eGames.com Holdings LLC, or eGames.com, in
      exchange for eGames.com&#8217;s payment of a purchase price of $2.0 million and assumption of specified liabilities relating to such pre-Merger business.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The Merger has been accounted for as a reverse acquisition in accordance with U.S. generally accepted accounting principles, or GAAP. Under this method of accounting, Brooklyn LLC was deemed the &#8220;acquiring&#8221; company and
      Brooklyn ImmunoTherapeutics, Inc. (then known as NTN Buzztime, Inc.) was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Operations prior to the Merger are those of Brooklyn LLC, and the historical financial statements of Brooklyn
      LLC became the historical financial statements of the Company with respect to periods prior to the completion of the Merger.</div>
    <div><br>
    </div>
    <div>Upon filing of the Form 10-K, the Company will report its consolidated financial results for the year ended December 31, 2021 with respect to the business of Brooklyn ImmunoTherapeutics, Inc.</div>
    <div> <br>
    </div>
    <div> <br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
